Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.
about
Treating refractory leukemias in childhood, role of clofarabineHigh-risk childhood acute lymphoblastic leukemiaPediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemiaChallenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaDetermination of minimal residual disease in leukaemia patients.Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.How and when should we monitor chimerism after allogeneic stem cell transplantation?Philadelphia positive acute lymphoblastic leukaemia of childhood.Childhood acute lymphoblastic leukaemia and relapse.Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Understanding the clinical implications of minimal residual disease in childhood leukemia.The detection and significance of minimal residual disease in acute and chronic leukemia.Methods of minimal residual disease (MRD) detection in childhood haematological malignancies.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.Minimal residual disease in acute lymphoblastic leukemiaReinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective reviewStatus of minimal residual disease testing in childhood haematological malignanciesRole of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.Improving outcomes for high-risk ALL: translating new discoveries into clinical care.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group.Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial.The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients.Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.
P2860
Q24647279-E508E95F-A57C-471B-A5E6-BF924A54D5E8Q33622837-214E1199-7033-4AF7-B5DB-23F861DC591DQ33828575-985B3242-8EAD-41B9-B15A-862F744453F7Q33831349-F2006ADB-2B4B-4D6C-9309-8F054B5416C9Q33886177-46778A9F-5D0F-4FF8-A69A-FB15005A0221Q33916091-0ABA3C77-C620-421F-9099-A807DFEF1927Q34343785-773F2056-83E2-4D9D-BFED-137415E884C3Q35094049-056BDD39-E537-494A-9CF0-26FE3DF78D9FQ35145184-5C679A83-0271-4A7C-91C9-BE1F641071FAQ35161219-B2389A1D-AB74-4F49-B462-DF1D73F1D3DAQ35606345-E62F87E9-D47B-4392-B03E-8FD3BF68FAC4Q35926907-724A36A9-5195-4D0B-ABDD-E561462CCBA1Q36228062-FE31F7B0-EF75-4D53-91D8-1F860A2E12D2Q36340652-E98835F7-EF14-468C-95BB-B2C6AEF35E66Q36366977-278D4AC1-2E8B-4490-8BD2-A61FD926854CQ36475317-FE5D2356-3AE2-4BD9-860A-5CA6A549FF69Q36648048-093054DC-3328-433A-A3FC-0604C0D97C9FQ36726108-A043CD14-3029-43FF-AB85-CEA7F69782F1Q36731636-3BC3EEAA-C778-48DA-AEE1-19EAC4071B4FQ36977560-CFC79BA2-E146-46BF-8765-72CCA216F8F4Q37077352-AB4CEAC4-368C-484E-AD34-76A7A586C360Q37124911-0B29C888-3C32-4A8A-9245-A916556665F9Q37233236-72AA86F9-F099-4412-BF7F-3858034E7914Q37246360-9A0908B2-3BDB-45C9-B317-C95C41C0DAF9Q37389544-3810DDA2-C1AB-47F5-AF7B-267EDBB60777Q37601706-2CADE8F4-2F12-47EF-B327-0F9C11892661Q37849259-36FD47B8-DBB5-4B76-90F3-CC9D48D18E0EQ38028808-14DBEB90-EF36-423A-87F6-34F80672FFFFQ38105123-0D36F07A-1274-4D78-9DC4-00D1559C1390Q38257363-8DB8BD69-6245-4A3D-8522-630BC5A78E19Q38681322-DF34A604-9A84-45E6-BB22-0B9C937561C1Q38749564-22C8127E-4C3B-4AB0-BEA2-0FB6E960CACEQ38815331-A71D7FEF-EB5B-4B74-9D62-48FA5F6FBA13Q39420711-1D34CB64-8386-4572-95D8-3BC903A2F0D4Q39877306-86F9A321-7485-4E06-B731-31397A0A59CBQ41688221-30073EE7-07F7-4A47-BCDE-C52874E67F43Q43610447-20D67C35-D8EC-4583-A78E-5FF5504947E6Q44505579-B78C21F0-397C-447D-831A-12839C0ACAA2Q45423288-2768066D-E0AC-47E3-B51B-2F566B469681Q46569726-56D1DC96-FE79-4BC4-BDCC-F0D42233B744
P2860
Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Minimal residual disease (MRD) ...... outcome in children with ALL.
@en
type
label
Minimal residual disease (MRD) ...... outcome in children with ALL.
@en
prefLabel
Minimal residual disease (MRD) ...... outcome in children with ALL.
@en
P2093
P356
P1433
P1476
Minimal residual disease (MRD) ...... t outcome in children with ALL
@en
P2093
Goulden NJ
Handgretinger R
Klingebiel T
Kreyenberg H
Niethammer D
P2888
P304
P356
10.1038/SJ.LEU.2402552
P577
2002-09-01T00:00:00Z
P5875
P6179
1029655664